News

President Torii Shingo of the Osaka Chamber of Commerce and Industry, also serving as the representative director and vice chairperson of Suntory Holdings Ltd., undertook a visit to the Nissin FULFIL Osaka Plant on January 26, 2024.

Since assuming the office, President Torii has championed the revival of manufacturing in Osaka. His visit to Nissin FUFIL was intended to assess the state of manufacturing in Osaka firsthand.

During the visit an overview of our parent company, Nissin Manufacturing, was provided. In addition, the inception of the medical business and its integration into Nissin FULFIL were explained. President Torii took a keen interest in the bone processing device currently in development, recognizing the formidable challenge of pioneering novel solutions in a new field. He remarked, “Developing something new to the world, something unprecedented, without established standards is difficult task.” expressing his admiration for the endeavor.

The delegation observed the operation of the bone processing device at our cutting-edge development site, gaining insight into the forefront in manufacturing. The presentation by the head of development, which included demonstrations of the device and its potential surgical applications, garnered significant interest from the visitors. Their messages of future support reinforced our commitment to advancing our business with unwavering determination and broad-based backing.

Members of the Medical Division spent 10 days in Singapore and Melbourne, to participate in Global Navigation, part of the Medical-Engineering Collaboration Innovation Promotion Project (AMED, Osaka Chamber of Commerce and Industry).

[Visit and Interview Destinations]

Singapore (Nov. 22 to 24): 11 facilities (Medical institutions, government agencies, and companies), 2 individual interviews (orthopedic surgeons)

Melbourne (Nov. 27 to 30): 9 facilities, 2 individual interviews (orthopedic surgeon, KOL)

We introduced the bone processing device to local orthopedic surgeons, they gave us favorable feedback, similar to the feedback at the exhibition in Japan, stating that it has “potential and value” and that the planned 3D processing function is “very promising.”

The KOL we interviewed in Melbourne introduced us to other well-known orthopedic surgeons, and we were able to have a web interview after returning to Japan.

We had the opportunity to expand our company’s network for overseas business development. One medical entity offered us new ideas, such as treatment for injured racehorses. We also received requests for brochures from several companies we visited.

We will continue to push forward with the development of the bone processing device, utilizing the power of other participating companies aiming at the global market.

In 2023, the Medical Division exhibited the bone processing device at 3 academic conferences, gathering the opinions of orthopedic doctors in various specializations about whether the bone processing device could be applied to a wide range of orthopedic fields.

At the Arthritis Conference, we received opinions related to each specialty area, such as “It seems to be good for arthritis and cases around the elbow.” (Olecranon fractures, etc.). At the Podiatric Surgery Conference, we received many questions regarding the strength of bone such as “Will the bones break after processing?”―perhaps because the foot bears the full weight of the body. We were again able to recognize the possibility of using bone processing device in various fields. In addition, the planned 3D processing function was well received at both conferences, and we were able to confirm once again that there is no discrepancy between the direction of the bone processing device aims for and the needs of doctors.

While addressing the issues that have emerged from the doctor’s feedback, we will continue to proceed with the direction of development for the bone processing device.